UroGen Pharma (NASDAQ:URGN) Issues Earnings Results

UroGen Pharma (NASDAQ:URGN) issued its quarterly earnings results on Wednesday. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29, RTT News reports. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter last year, the firm posted ($0.68) EPS.

UroGen Pharma Stock Down 1.1 %

URGN stock traded down $0.14 during mid-day trading on Thursday, reaching $12.10. 303,960 shares of the company traded hands, compared to its average volume of 502,973. UroGen Pharma has a fifty-two week low of $10.60 and a fifty-two week high of $20.70. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. The firm’s 50 day moving average price is $12.82 and its 200 day moving average price is $14.20. The stock has a market cap of $283.75 million, a price-to-earnings ratio of -3.70 and a beta of 1.12.

Analyst Upgrades and Downgrades

URGN has been the topic of several recent analyst reports. Oppenheimer restated an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. Guggenheim began coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target on the stock. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.